The Agile Therapeutics Inc. (NASDAQ:AGRX) is going up by 21.90% in today’s trading session, a rise equivalent to 0.3% of the stock’s price from yesterday’s market close. A news came out on 11/14/19 stating that Agile Therapeutics Announces FDA Extension of Twirla(R) NDA Review Period by WSJ. The lowest point that the shares touched during the trading session was $1.35, while the peak of the day was recorded at a share price of $1.49. AGRX finished the previous session at $1.37 according to the data provided by Barchart, while the trading volume was observed to be $3182913.

In the 100 days of trading, AGRX managed to top a 1.30% Moving average. Additionally, Agile Therapeutics Inc. shares have achieved a 52-week range between 0.35 and 2.97 alongside 100 days raw stochastic set at 48.79%.

The number of shares outstanding, according to the fundamentals of the company, is set at 94.70M, equal to the value of $129.74M in market capitalization. In the last 30 days, Agile Therapeutics Inc. shares went down by -45.17%, adding 2.97 to growth in value, on top of a +365.26% boost since 10/18/19.

Agile Therapeutics Inc. (NASDAQ:AGRX) Analyst’s Estimates

Agile Therapeutics Inc. (AGRX) could record at least -$0.08 per share in quarterly earnings in the upcoming report on 03/04/2020, a number that would actually represent a decrease of -0.36 YOY.

According to the average analyst rating, Agile Therapeutics Inc. would be rated as Buy. Out of 6 different analysts monitoring AGRX stock, 6 analysts rate the stock as a BUY, 0 suggest to give the rating of HOLD, 0 indicate that AGRX is an OVERWEIGHT, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERWEIGHT.

On April 12, 2019, the stock earned a Resumed rating due to a new analyst call from Janney, while analysts from Maxim Group believe that the stock is set at Buy, as concluded on November 29, 2018. William Blair, is still rather wary about the stock, deciding to keep the rating at Mkt Perform as confirmed through a call on December 26, 2017.

H.C. Wainwright, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on October 02, 2017, giving the stock a Buy rating.

AGRX Key Ratios To Watch:

The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at -54.20%. Beta value of the stock is recorded at 0.63. Additionally, Agile Therapeutics Inc. is recording price volatility of 15.73% for the period of the last seven days and 21.39% in the last 30 days.

Agile Therapeutics Inc. (NASDAQ:AGRX) Technical Outlook

For the period of the last 50 days, Agile Therapeutics Inc. had its Raw Stochastic average set at 48.79% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 48.79%. Stochastic %K for Agile Therapeutics Inc., with the last 20 days included, was set at 43.75%, having Stochastic %D topping 53.47%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be encouraging for Agile Therapeutics Inc. stocks with recording 137.89% in metrics.

Agile Therapeutics Inc. Insider Watch:

Similarly, 54.90% of the company’s float is held by institutions – and there are 38 institutions in total holding shares of this company. The top three institutional holders of AGRX stocks are: Perceptive Advisors Llc with ownership of $12.71 million, which is approximately 10726750 of the company’s shares; Investor AB, holding 3510189 shares of the stock with an approximate value of $4.16 million; and Renaissance Technologies, LLC, currently with more than 2427100 shares of the company valued at $2.88 million. Positions in Agile Therapeutics Inc. stocks held by institutional investors has been changing actively in the past six months, a period during which there were 14 insider purchases amounting to 2548263 shares. Similarly, there were 2 sale transactions amounting to 4575640 shares, with the net shares purchased during the last six months reaching -2,027,377.